APTOF — Aptose Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Aptose Biosciences Inc Files For Mixed Shelf Of Up To $200 Mln
Brief: Aptose Strengthens Board Of Directors With Appointment Of Bernd Seizinger
Brief: Aptose's New “G3” Formulation Of Luxeptinib Boosts Bioavailability
Brief: Aptose Biosciences Inc - QTRLY Loss Per Share $0.11
Brief: Aptose Receives Deficiency Letter From Nasdaq Listing Qualifications Department
Brief: Aptose Biosciences Inc Presents Highlights From Corporate Update And Kol Event
Brief: Aptose Biosciences Q1 Loss Per Share C$0.12
Brief: Aptose Receives Fast Track Designation For HM43239
Brief: Aptose Biosciences- Luxeptinib Preclinical Data Extend Potential Applications From Oncology To Inflammation
Brief: Aptose Announces Executive Management Changes
Brief: Aptose Reports Results For The Fourth Quarter And Full Year 2021
Brief: Aptose Provides Update On Apto-253 Program
U.S. STOCKS ON THE MOVE-Tesla, Beyond Meat, Novavax, Chinese stocks
Brief: Aptose Biosciences - Hm43239 Demonstrates Durable Clinical Benefit In Acute Myeloid Leukemia
Brief: Aptose Reports Results For The Third Quarter 2021
Brief: Aptose Expands Senior Leadership Team
Brief: Aptose Reports Q2 2021 Results
U.S. RESEARCH ROUNDUP-Atotech, Lifestance Health Group, Principal Financial Group
Brief: Aptose Reports Results For The First Quarter 2021